For people with 4-14 MHDs per month,

Emgality delivered significantly more migraine-free days vs placebo1

Emgality prevented up to 4.7 mean MHDs per month vs up to 2.8 mean MHDs with placebo, on average (p<0.001)1

Change from baseline in mean monthly MHDs1,9b

Emgality mhd reduction

bLeast-square means and 95% confidence intervals are presented.
cEarliest post-baseline, prespecified assessment.

EVOLVE-1: -3.7 mean MHDs with Emgality in the first month, on average vs -1.7 mean MHDs with placebo

EVOLVE-2: -3.9 mean MHDs with Emgality in the fi rst month, on average vs -1.2 mean MHDs with placebo

Emgality significantly reduced the mean number of monthly MHDs that acute medication was used over Months 1 to 6 (p<0.001)1,10,11

  • EVOLVE-1: -4.0 MHDs per month with Emgality vs -2.2 MHDs per month with placebo
  • EVOLVE-2: -3.7 MHDs per month with Emgality vs -1.9 MHDs per month with placebo

See study design for EVOLVE-1 and EVOLVE-2

SELECT IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria, and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Emgality is available by prescription only.


Please see Full Prescribing Information, including Patient Information for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ HCP ISI 27SEP2018